Ex Vivo Culture of Umbilical Cord Blood Stem Cells for Adult Transplantation

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: 4R44HL087473-02
Agency Tracking Number: HL087473
Amount: $818,915.00
Phase: Phase II
Program: SBIR
Awards Year: 2008
Solitcitation Year: 2008
Solitcitation Topic Code: N/A
Solitcitation Number: PHS2007-2
Small Business Information
QUALITY BIOLOGICAL, INC.
QUALITY BIOLOGICAL, INC., 7581 LINDBERGH DRIVE, GAITHERSBURG, MD, 20879
Duns: 103926911
Hubzone Owned: Y
Woman Owned: Y
Socially and Economically Disadvantaged: Y
Principal Investigator
 RONALD BROWN
 (301) 840-9331
 BROWNR@QUALITYBIOLOGICAL.COM
Business Contact
Phone: (301) 840-8950
Email: whitakerb@qualitybiological.com
Research Institution
N/A
Abstract
DESCRIPTION (provided by applicant): The overall goal of this proposal is to delineate the ex vivo serum-free culture conditions to expand CD34+ cells derived from cryopreserved umbilical cord blood cells to levels that will support its use in the adult transplant setting. The disadvantage of umbilical cord blood for adult transplants has been attributed to having too few long-term engrafting cells/hematopoietic stem cells in the cord blood. Studies presented herein suggest that this problem can be circumvented based on 1) the development of a clinical grade serum-free medium designated especially for the ex vivo expansion of CD 34+ cells derived from cord blood, 2) the successful expansion of CD 34+ cells from cryopreserved umbilical cord blood to levels adequate to support adult transplantation using the clinical grade serum-free medium with the early acting cytokines, Flt-3 ligand, stem cell factor, thrombopoietin, and Interleukin 6, and 3) the ability of these ex vivo cultured CD 34+ cells to engraft long-term in the fetal sheep model for human hematopoiesis. The Phase I milestone will be to repeat and extended these initial studies and assess the long-term engrafting ability of these cultured CD 34+ cells in increased numbers of animals and evaluate longer culture periods. These critical results will form the basis of the Phase II proposal to determine if 1) the long-term engrafting cells are being expanded or maintained under these ex vivo serum-free culture conditions, 2) define the optimal culture period yielding high quality long-term engrafting cells, and 3) evaluate other cytokines in combination with the above cytokine platform. The ability to expand the long-term engrafting cells would be invaluable in the adult transplant setting. The efforts from this proposal will yield clinically relevant data on the optimal conditions necessary for use of cryopreserved cord blood for adult transplantation. . The products derived form this proposal will support the ex vivo culture of CD34+ cells derived from cryopreserved umbilical cord blood and the maintenance of these cells ability to engraft long-term. Since cord blood has few long-term engrafting cells /hematopoietic stem cells it can only be used for infant transplantation, not adult transplantation. The ability to develop a serum-free clinical grade culture system that will support the expansion of the long-term engrafting cells will facilitate the clinical use of these cells in adult transplants.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government